Sensei Biotherapeutics To Present Preclinical Data On SNS-103 At The CRI-ENCI Eighth International Immunotherapy Conference September 8-11, 2024
Portfolio Pulse from Benzinga Newsdesk
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) will present preclinical data on its cancer therapeutic SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference in September 2024.
September 04, 2024 | 8:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sensei Biotherapeutics will present preclinical data on SNS-103, a potential cancer therapeutic, at a major immunotherapy conference in September 2024.
The announcement of presenting preclinical data at a major conference could generate investor interest and optimism about the company's pipeline, potentially leading to a positive short-term impact on SNSE's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100